Next Article in Journal
Challenges for Economic Evaluation of Health Care Strategies to Contain Antimicrobial Resistance
Next Article in Special Issue
Phenylboronic Acids Probing Molecular Recognition against Class A and Class C β-lactamases
Previous Article in Journal
Gut Bacteria of Water Monitor Lizard (Varanus salvator) Are a Potential Source of Antibacterial Compound(s)
Previous Article in Special Issue
Characterization of a Carbapenem-Resistant Kluyvera Cryocrescens Isolate Carrying Blandm-1 from Hospital Sewage
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Letter

Stability of Biological Activity of Frozen β-lactams over Time as Assessed by Time-Lapsed Broth Microdilutions

1
Research Institute of the McGill University Health Centre, Montréal, QC H4A 3J1, Canada
2
Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montréal, QC H4A 3J1, Canada
3
McGill Interdisciplinary Initiative in Infection and Immunity, McGill University, Montréal, QC H3A 1Y2, Canada
*
Author to whom correspondence should be addressed.
Submission received: 27 August 2019 / Revised: 20 September 2019 / Accepted: 22 September 2019 / Published: 25 September 2019

Abstract

:
To evaluate the antimicrobial agent’s stability stored at −80 °C, six β-lactams (meropenem, ertapenem, imipenem, ceftriaxone, ceftazidime, and piperacillin-tazobactam) were studied using the broth microdilution (BMD). The minimum inhibitory concentration (MIC) remained accurate with the same amount of frozen drug for at least six months. Thereafter, there was a diminishing drug concentration due to instability. At this temperature, most β-lactams can be frozen as a stock concentration for up to six months without a significant loss in antibiotic activity.

Antibiotic susceptibility testing (AST) is routinely performed in both clinical and research laboratories yielding important data for clinical and epidemiological purposes [1]. For most organisms, the gold standard in AST remains the broth microdilution assay (BMD), a method that determines the minimum inhibitory concentrations (MICs) of each tested antibiotic against the bacterial isolate of interest [2]. While usually reproducible, there can be important variability in any MIC measurement. This may occur through biological variation such as “MIC creeps” as well as assay variation in terms of inoculum preparation, media, incubation temperature and time, and variation between laboratories [3]. In order for the MIC to be determined, the concentrations and the biological activity of the antibiotics used in the assays must also be predictably accurate such that variations in the MIC are not reflections of antibiotic degradation or loss of activity through other mechanisms. To the best of our knowledge, the stability of biological activity of reconstituted β-lactams antibiotics stored at –80 °C has not been determined. Therefore, the purpose of this study was to evaluate the stability of these antimicrobial agents in terms of their biological activity for use in BMD assays that were carried out periodically over a ten-month period.
Six β-lactams were purchased from different pharmaceutical companies: meropenem trihydrate 1 g (Fresenius Kabi, Toronto, ON, CA), ertapenem sodium 1 g (Merck Canada Inc., Kirkland, QC, CA), imipenem/cilastatin sodium 500 mg/500 mg (Sandoz Canada Inc., Boucherville, QC, CA), ceftriaxone sodium 2 g, ceftazidime pentahydrate 2 g (Sterimax Inc., Oakville, ON, CA), and piperacillin sodium salt 1 g (Sigma-Aldrich, St Louis, MO, USA) combined with Tazobactam sodium salt 250 mg (Cayman Chemical, Ann Arbor, MI, USA). For the meropenem, ertapenem, imipenem, ceftriaxone and ceftazidime, these were clinical grade reagents. For the piperacillin and tazobactam, the purity was >95% [4,5,6,7,8,9,10] and they were dissolved according to the manufacturer’s instructions and stock solutions were prepared in sterile water and stored in aliquots of 2 mL at −80 °C (Table 1). The temperature regulation of the freezer was routinely monitored through daily temperature checks and the temperature was maintained at −80 ± 2 °C throughout the study period without any recorded deviation.
Broth microdilutions were repeatedly performed on a group of 24 KPC producing Klebsiella pneumoniae over a period of six months using the standard technique [3] and aliquots of the antibiotics were thawed at room termpature and diluted to the working concentration ranges using sterile water. As a control for each experiment, Escherichia coli ATCC 25922 was used as the recommended quality control strain to use when performing AST for Enterobacteriaceae according to the CLSI M100 [3].
The MICs remained accurate with the same amount of frozen drug for at least six months. However, thereafter, there was a loss of biological activity as evidenced by what appeared to be rising MICs (see Table 2 for the results for the reference strain with well characterized MICs) but was, in fact diminishing drug biological activity due to instability under the storage conditions. This was demonstrated by confirming that the MICs remained within the expected reference range when the AST of the quality control strains were verified by disc diffusion assay and by Vitek2 AST testing. This was then further confirmed by repeating the BMDs using frenshly prepared new drug lots.
In conclusion, it appears that most β-lactams can be frozen as a stock concentration for up to six months at −80 °C without a significant loss in antibiotic activity. This can allow for cost savings via bulk purchasing and alioquoting in the laboratory and could also have clinical applications with unused doses in the clinical pharmacy. Beyond six months caution is advised and the biological activity of the antibiotics need verification.

Author Contributions

All members have contributed to various degrees. A.L., M.P.C., and T.L. conceived the idea, G.L., A.L., M.P.C., and T.L. designed the experiments, GL performed experiments. All authors contributed to the discussion of the results and preparation of the manuscript.

Funding

This research received no external funding.

Acknowledgments

The authors thank Annie Fortin, Martin Raymond, and Cynthia Perreira for providing logistical support and the Clinical Microbiology Laboratory of the McGill University Health Centre. Dr. Lee receives research salary support from the Fonds de Recherche du Québec—Santé and funded this work through institutional discretionary funds. Matthew P. Cheng receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Santé Québec.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Maugeri, G.; Lychko, I.; Sobral, R.; Roque, A.C.A. Identification and Antibiotic-Susceptibility Profiling of Infectious Bacterial Agents: A Review of Current and Future Trends. Biotechnol. J. 2019, 14, e1700750. [Google Scholar] [CrossRef] [PubMed]
  2. Flentie, K.; Spears, B.R.; Chen, F.; Purmort, N.B.; DaPonte, K.; Viveiros, E.; Phelan, N.; Krebill, C.; Flyer, A.N.; Hooper, D.C.; et al. Microplate-based surface area assay for rapid phenotypic antibiotic susceptibility testing. Sci. Rep. 2019, 9, 237. [Google Scholar] [CrossRef] [PubMed]
  3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 27th Informational Supplement. M100-S28; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018. [Google Scholar]
  4. Merepenem for Injection—Fresenius-Kabi. Available online: https://www.fresenius-kabi.com/en-ca/documents/Meropenem-PM-ENG-110617.pdf (accessed on 24 September 2019).
  5. Ertapenem for Injection—Merck Canada Inc. Available online: https://www.merck.ca/static/pdf/INVANZ-PM_E.pdf (accessed on 24 September 2019).
  6. Imipenem/Cilastatin for Injection—Sandoz Canada Inc. Available online: https://www.sandoz.ca/sites/www.sandoz.ca/files/Imipenem_Cilastatin_Product_Monograph.pdf (accessed on 24 September 2019).
  7. Ceftriaxone Sodium for Injection—SteriMax Inc. Available online: http://sterimaxinc.com/wp-content/uploads/2016/03/1.3.1-SteriMax-English-PM-February-8-20163.pdf (accessed on 24 September 2019).
  8. Ceftazidime for Injection—SteriMax Inc. Available online: http://sterimaxinc.com/wp-content/uploads/2015/08/ceftazidime-monograph.pdf (accessed on 24 September 2019).
  9. Piperacillin Sodium Salt—Sigma-Aldrich. Available online: https://www.sigmaaldrich.com/Graphics/COfAInfo/SigmaSAPQM/SPEC/P8/P8396/P8396-BULK-SIGMA.pdf (accessed on 24 September 2019).
  10. Tazobactam Sodium Salt—Cayman Chemical. Available online: https://www.caymanchem.com/pdfs/17185.pdf (accessed on 24 September 2019).
Table 1. Stock concentrations of the beta-lactams.
Table 1. Stock concentrations of the beta-lactams.
AntibioticsStock Concentrations (g/L)
Meropenem11.2
Ertapenem16.5
Imipenem5.7
Ceftriaxone25.7
Ceftazidime12.9
Piperacillin16
Tazobactam0.25
Table 2. Antibiotic activity for 6 β-lactams stored at −80 °C.
Table 2. Antibiotic activity for 6 β-lactams stored at −80 °C.
Duration of Antibiotic Storage at −80 °C (days)MIC of β-Lactams Tested (mg/L)
MERETPIMICTXCTZb PTZ
00.0160.0080.120.060.251/4
140.0160.0080.120.060.254/4
490.0160.0040.120.060.254/4
1790.0160.0080.250.120.52/4
2860.250.0620.528/4
a MIC QC ranges (mg/L)
E. coli ATCC259220.008–0.0160.004–0.0160.06–0.250.03–0.120.06–0.51/4–4/4
a MIC Quality Control ranges according to CLSI, 2018 [3]. These are the expected MIC ranges for the different antibiotics for the E. coli ATCC25922 strain and are the same for each time point of antibiotic storage. Abbreviations: MER-meropenem, ETP-ertapenem, IMI-imipenem, CTX-ceftriaxone, CTZ-ceftazidime, PTZ-piperacillin-tazobactam.CLSI M100 [3] suggests using a fixed concentration of tazobactam at 4 mg/L for b PTZ broth microdilution assays.

Share and Cite

MDPI and ACS Style

Leite, G.; Lawandi, A.; Cheng, M.P.; Lee, T. Stability of Biological Activity of Frozen β-lactams over Time as Assessed by Time-Lapsed Broth Microdilutions. Antibiotics 2019, 8, 165. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics8040165

AMA Style

Leite G, Lawandi A, Cheng MP, Lee T. Stability of Biological Activity of Frozen β-lactams over Time as Assessed by Time-Lapsed Broth Microdilutions. Antibiotics. 2019; 8(4):165. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics8040165

Chicago/Turabian Style

Leite, Gleice, Alexander Lawandi, Matthew P. Cheng, and Todd Lee. 2019. "Stability of Biological Activity of Frozen β-lactams over Time as Assessed by Time-Lapsed Broth Microdilutions" Antibiotics 8, no. 4: 165. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics8040165

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop